Idenix Pharmaceuticals (IDIX): 8K filing just out reveals a new IP disp...

Reply Private New

Replies (1) Next 10 Prev Next

Send PM Follow Ignore

Followers	840
Posts	121408
Boards Moderated	8
Alias Born	09/05/2002

DewDiligence

Re: None

Friday, 01/19/2007 5:44:48 PM

Friday, January 19, 2007 5:44:48 PM

8K filing just out reveals a new IP dispute with U.
of Alabama–Birmingham (UAB). The new dispute
concerns Tyzeka/Sebivo. An older dispute between
the parties concern milestones and potential royalties
on NM283, as detailed in prior SEC filings.

http://biz.yahoo.com/e/070119/idix8-k.html

>>
Idenix Pharmaceuticals, Inc. (“Idenix”) was notified on January 17, 2007 that the Board of Trustees of the University of Alabama, on behalf of the University of Alabama-Birmingham and the UAB Research Foundation, filed a complaint on January 12, 2007 in the United States District Court for the Northern District of Alabama Southern Division naming Idenix, Le Centre National de la Recherche Scientifique (“CNRS”) and L’Université Montpellier II (“Montpellier”). Idenix has not been formally served with the complaint. The complaint alleges that a former employee of the University of Alabama-Birmingham is a co-inventor of certain patents related to the use of ß-L-2’-deoxy-nucleosides for the treatment of hepatitis B assigned to Idenix, CNRS and Montpellier and which cover the use of telbivudine, Idenix’s drug product for the treatment of hepatitis B. Idenix is reviewing this claim with inside and outside legal counsel and intends to vigorously defend the lawsuit.
<<

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”